References
- European Association of Urology. Guidelines. Non-invasive muscle bladder cancer. [cited 2019 Dec 15]. Available at: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/
- European Commission. ECIS - European Cancer Information System. Incidence and mortality of bladder cancer in Europe. [cited 2018 Sep 15]. Available at: https://ecis.jrc.ec.europa.eu/explorer.php?$1-All$2-All$4-1,2$3-38$6-0,14$5-2008,2008$7-7,8$0-0$CEstByCountry$X0_8-3$CEstRelative$X1_8-3$X1_9-AE28
- Compérat E, Larré S, Roupret M, Neuzillet Y, Pignot G, Quintens H, et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch 2015; 466: 589-94. doi: 10.1007/s00428-015-1739-2.
- Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63: 234-41. doi: 10.1016/j.eururo.2012.07.033
- UICC International Union Against Cancer. Urinary bladder. In: Sobin LH, Gospodarowicz MK, Wittekind Ch, editors. TNM classification of malignant tumours, 7th edition. Chichester: Wiley-Blackwell, 2009. p. 262-5.
- Slora. Slovenia and cancer. Basic epidemiologic data on cancer. Urinary bladder (C67). [cited 2018 Mar 03]. Available at: http://www.slora.si/documents/11561/20219/bladder.pdf?version=1.2
- Lee SH, Hu W, Matulay JT, Silva MV, Owczarek TB, Kim K, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell 2018; 173: 515-28.e17. doi: 10.1016/j.cell.2018.03.017
- Wang S, Gao D, Chen Y. The potential of organoids in urological cancer research. Nat Rev Urol 2017; 14: 401-14. doi: 10.1038/nrurol.2017.65
- Zainfeld D, Daneshmand S. Transurethral resection of bladder tumors: improving quality through new techniques and technologies. Curr Urol Rep 2017; 18: 34. doi: 10.1007/s11934-017-0680-0
- American Urological Association. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO Guideline (2017). [2019 Dec 15]. Available at: https://www.auanet.org/guidelines/bladder-cancer-non-metastatic-muscle-invasive
- Kassouf W, Traboulsi SL, Kulkarni GS, Breau RH, Zlotta A, Fairey A, et al. CUA guidelines on the management of non-muscle invasive bladder cancer. Can Urol Assoc J 2015; 9: E690-704. doi: 10.5489/cuaj.3320
- Massarweh NN, Cosgriff N, Slakey DP. Electrosurgery: history, principles, and current and future uses. J Am Coll Surg 2006; 202: 520-30. doi: 10.1016/j. jamcollsurg.2005.11.017
- Osman Y, Harraz AM. A review comparing experience and results with bipolar versus monopolar resection for treatment of bladder tumors. Curr Urol Rep 2016; 17: 21. doi: 10.1007/s11934-016-0579-1
- Mashni J, Godoy G, Haarer C, Dalbagni G, Reuter VE, Al-Ahmadie H, et al. Prospective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findings. Int Urol Nephrol 2014; 46: 1699-705. doi: 10.1007/s11255-014-0719-9
- Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol 2016; 69: 231-44. doi: 10.1016/j. eururo.2015.05.050
- Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intra-vesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 2008; 53: 709-19. doi: 10.1016/j.eururo.2008.01.015
- Arends TJ, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol 2016; 69: 1046-52. doi: 10.1016/j. eururo.2016.01.006
- Malmstrom PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009; 56: 247-56. doi: 10.1016/j.eururo.2009.04.038
- van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV; EORTC Genito-Urinary Tract Cancer Group. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003; 44: 429-34. doi: 10.1016/s0302-2838(03)00357-9
- Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180-3. doi: 10.1016/s0022-5347(17)58737-6
- Sylvester, RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964-70. doi: 10.1097/01.ju.0000034450.80198.1c
- Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 2007; 52: 1398-406. doi: 10.1016/j. eururo.2007.04.062
- Flsenstein KM, Theodorescu D. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nat Rev Urol 2018; 15: 92-111. doi: 10.1038/nrurol.2017.179
- Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009; 459: 262-5. doi: 10.1038/nature07935
- Liu X, Ory V, Chapman S, Yuan H, Albanese C, Kallakury B, et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 2012; 180: 599-607. doi: 10.1016/j.ajpath.2011.10.036
- Chapman S, Liu X, Meyers C, Schlegel R, McBride AA. Human keratinocytes are efficiently immortalized by a Rho kinase inhibitor. J Clin Invest 2010; 120: 2619-26. doi: 10.1172/JCI42297
- Santos CP, Lapi E, Martínez de Villarreal J, Alvaro-Espinosa L, Fernandez-Barral A, Barbáchano A, et al. Urothelial organoids originating from Cd49fhigh mouse stem cells display Notch-dependent differentiation capacity. Nat Commun 2019; 10: 4407. doi: 10.1038/s41467-019-12307-1.
- Vasytin I, Zerihun L, Ivan C, Atala A. Bladder organoids and spheroids: potential tools for normal and diseased tissue modelling. Anticancer Res 2019; 39: 1105-18. doi: 10.21873/anticanres.13219
- Smith YC, Grande KK, Rasmussen SB, O’Brien AD. Novel three-dimensional organoid model for evaluation of the interaction of uropathogenic Escherichia coli with terminally differentiated human urothelial cells. Infect Immun 2006; 74: 750-7. doi: 10.1128/IAI.74.1.750-757.2006
- Matulay JT, Barlow LJ, Silva MV, Chua CW, Benson MC, McKiernan JM, et al. Genetic mutations in patient-derived bladder tumor organoids mimic parental tumor samples [abstract PD38-07]. J Urol 2016; 195(Suppl): e926. doi: 10.1016/j.juro.2016.02.1487
- Osborn SL, Thangappan R, Luria A, Lee JH, Nolta J, Kurzrock EA, et al. Induction of human embryonic and induced pluripotent stem cells into urothelium. Stem Cells Transl Med 2014; 3: 610-9. doi: 10.5966/sctm.2013-0131
- Kang M, Kim HH, Han YM. Generation of bladder urothelium from human pluripotent stem cells under chemically defined serum- and feeder-free system. Int J Mol Sci 2014; 15: 7139-57. doi: 10.3390/ijms15057139
- Banerjee S, Southgate J. Bladder organoids a step towards personalised cancer therapy? Transl Androl Urol 2019; 8: S300-2. doi: 10.21037/tau.2019.06.10
- Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, et al. Organoid modeling of the tumor immune microenvironment. Cell 2018; 175: 1972-88. doi: 10.1016/j.cell.2018.11.021
- Scher HI, Heller G, Molina A, Attard G, Danila DC, Jia X, et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol 2015; 33: 134855. doi: 10.1200/JCO.2014.55.3487
- Lozar T, Gersak K, Cemazar M, Grasic Kuhar C, Jesenko T. The biology and clinical potential of circulating tumor cells. Radiol Oncol 2019; 53: 131-47. doi: 10.2478/raon-2019-0024
- Shin K, Lee J, Guo N, Kim J, Lim A, Qu L, et al. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature 2011; 472: 110-4. doi: 10.1038/nature09851
- Mullenders J, de Jongh E, Brousali A, Roosen M, Blom JPA, Begthel, et al. Mouse and human urothelial cancer organoids: a tool for bladder cancer research. Proc Natl Acad Sci U S A 2019; 116: 4567-74. doi: 10.1073/pnas.1803595116.